Belite Bio reported a GAAP net loss of USD 25.3 million for Q4 FY2025 and a GAAP net loss of USD 77.6 million for FY2025. R&D expenses were USD 14.6 million in Q4 FY2025 and USD 45.4 million in FY2025, while selling, general and administrative expenses were USD 13.5 million in Q4 FY2025 and USD 38.8 million in FY2025. Other income was USD 2.8 million in Q4 FY2025 and USD 6.6 million in FY2025. As of Dec. 31, 2025, Belite Bio had cash and cash equivalents of USD 352.9 million and investments of USD 419.7 million. On the business front, Belite Bio said the Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease type 1 met its primary endpoint, showing a 35.7% reduction in the growth rate of macular lesions versus placebo, and the company remains on track to submit an NDA to the FDA in Q2 2026. The company also said it completed enrollment in the Phase 2/3 DRAGON II trial, with 72 subjects enrolled as of Feb. 27, 2026, and that the Phase 3 PHOENIX trial in geographic atrophy completed enrollment with 530 subjects, with an interim analysis expected. Belite Bio also highlighted the completion of a USD 402 million underwritten public offering of ADSs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020600PRIMZONEFULLFEED9663781) on March 02, 2026, and is solely responsible for the information contained therein.
Comments